Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polidocanol is a non-ionic detergent and sclerosing agent used primarily to treat small varicose veins (spider veins and reticular veins) of the lower extremities. It is also indicated for incompetent great saphenous veins, accessory saphenous veins, and visible varicose veins above and below the knees. Polidocanol works by locally damaging the endothelium of blood vessels; this injury leads to platelet aggregation at the site, followed by occlusion of the vessel with a dense network of platelets, cellular debris, and fibrin. The occluded vein is eventually replaced with connective fibrous tissue. Chemically, it consists of a polar hydrophilic (dodecyl alcohol) chain and an apolar hydrophobic (polyethylene oxide) chain. In addition to its use as a sclerosant in injectable form under brand names such as Asclera and Varithena, polidocanol has topical applications as a local anesthetic and antipruritic in ointments for eczema or dry skin[1][2][3][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polidocanol.